Market Overview:
The global immunotherapy drugs for multiple myeloma market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The growth in this market can be attributed to factors such as the increasing incidence of multiple myeloma, rising awareness about available treatment options, and the launch of novel therapies. The global immunotherapy drugs for multiple myeloma market is segmented on the basis of type into INF-α, IL-6, and rituximab. The INF-α segment is expected to account for the largest share of the global immunotherapy drugs for multiple myeloma market in 2018. This segment is also projected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The IL-6 segment is expected to grow at a higher CAGR than other segments during the forecast period owing to its growing use in combination with other therapies. On the basis of application, hospital accounted for majority share (XX%)of total revenue generated by sales Immunotherapy Drugs For Multiple Myelomas Market In 2017 And Is Expected To Grow At A Highest Rate Over The Forecast Period .
Product Definition:
Immunotherapy drugs are used to help the body's immune system fight cancer. Immunotherapy drugs for multiple myeloma work by helping the body's immune system find and destroy cancer cells.
INF-α:
INF-α is a protein that acts as an inhibitor of the proteasome. Proteasomes are responsible for degrading misfolded proteins, damaged organelles and cellular debris. The accumulation of these materials results in the formation of plaques which can result in neurodegeneration, cardiomyopathy or nephropathy and eventually myeloma.
IL-6:
IL-6 is a cytokine that acts as an interleukin in the immune system. Cytokines are proteins that are produced by certain cells of the immune system such as T cells, B cells, and natural killer (NK) Cells. There are many different types of cytokines but most of them have similar functions.
Application Insights:
Clinic application led the global immunotherapy drugs for multiple myeloma market in 2017. This is attributed to rising awareness about availability of affordable treatment options and increasing number of clinics offering these therapies. For instance, Rising Myeloma Institute offers a sliding scale fee schedule for patients diagnosed with relapsed or refractory MM. The cost of each cycle of therapy at this institute is USD 12,500 as compared to USD 3500 charged by other private hospitals and cancer centers in India.
Drug center application was the largest segment owing to high usage rates and wide product portfolio available in leading pharmaceutical companies across the globe which includes AbbVie (U.S.), Novartis (Switzerland), Pfizer Inc., Johnson & Johnson (U.S.), sanofi-aventis ULC (Canada), Bayer HealthCare LLC/Mallinckrodt Pharmaceuticals LLC (Uruguay), Aurobindo Pharma Ltd., etcetera.
Regional Analysis:
North America dominated the global immunotherapy drugs market in 2017. This can be attributed to the presence of key players, high R&D investment by companies and government support for clinical trials. In addition, favorable reimbursement policies for patients and healthcare providers are also expected to drive growth during the forecast period. Asia Pacific is anticipated to witness lucrative growth over the forecast period owing to increasing number of drug approvals by regulatory agencies as well as increased usage of these drugs in combination with other therapies in treatment settings different from that approved by regulatory agencies. For instance, Sun Pharma’s Zydeliglucon (idelixid) was approved for use only under hospital conditions whereas it is being used off-label at an affordable price point suitable for self-payment or out-of-pocket payment systems prevalent across India.
Growth Factors:
- Increasing incidence of multiple myeloma
- Growing demand for novel and targeted therapies for multiple myeloma
- Rising awareness about immunotherapy drugs for multiple myeloma
- Technological advancements in the field of immunotherapy drugs development
- Availability of government funding and support for research on immunotherapy drugs
Scope Of The Report
Report Attributes
Report Details
Report Title
Immunotherapy Drugs for Multiple Myeloma Market Research Report
By Type
INF-α, IL-6, Rituximab, Other
By Application
Hospital, Drug Center, Clinic, Other
By Companies
Tonghua Dongbao Pharmaceutical, Sumitomo , Merck, Biogen, Schering-Plough, Roche, Glaxo, Chiron
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
195
Number of Tables & Figures
137
Customization Available
Yes, the report can be customized as per your need.
Global Immunotherapy Drugs for Multiple Myeloma Market Report Segments:
The global Immunotherapy Drugs for Multiple Myeloma market is segmented on the basis of:
Types
INF-α, IL-6, Rituximab, Other
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Drug Center, Clinic, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Tonghua Dongbao Pharmaceutical
- Sumitomo
- Merck
- Biogen
- Schering-Plough
- Roche
- Glaxo
- Chiron
Highlights of The Immunotherapy Drugs for Multiple Myeloma Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- INF-α
- IL-6
- Rituximab
- Other
- By Application:
- Hospital
- Drug Center
- Clinic
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Immunotherapy Drugs for Multiple Myeloma Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Immunotherapy drugs are used to treat multiple myeloma. These drugs help the bodyu2019s immune system fight cancer cells.
Some of the key players operating in the immunotherapy drugs for multiple myeloma market are Tonghua Dongbao Pharmaceutical, Sumitomo , Merck, Biogen, Schering-Plough, Roche, Glaxo, Chiron.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Immunotherapy Drugs for Multiple Myeloma Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Immunotherapy Drugs for Multiple Myeloma Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Immunotherapy Drugs for Multiple Myeloma Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Immunotherapy Drugs for Multiple Myeloma Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Immunotherapy Drugs for Multiple Myeloma Market Size & Forecast, 2018-2028
4.5.1 Immunotherapy Drugs for Multiple Myeloma Market Size and Y-o-Y Growth
4.5.2 Immunotherapy Drugs for Multiple Myeloma Market Absolute $ Opportunity
Chapter 5 Global Immunotherapy Drugs for Multiple Myeloma Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Immunotherapy Drugs for Multiple Myeloma Market Size Forecast by Type
5.2.1 INF-α
5.2.2 IL-6
5.2.3 Rituximab
5.2.4 Other
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Immunotherapy Drugs for Multiple Myeloma Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Immunotherapy Drugs for Multiple Myeloma Market Size Forecast by Applications
6.2.1 Hospital
6.2.2 Drug Center
6.2.3 Clinic
6.2.4 Other
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Immunotherapy Drugs for Multiple Myeloma Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Immunotherapy Drugs for Multiple Myeloma Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Immunotherapy Drugs for Multiple Myeloma Analysis and Forecast
9.1 Introduction
9.2 North America Immunotherapy Drugs for Multiple Myeloma Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Immunotherapy Drugs for Multiple Myeloma Market Size Forecast by Type
9.6.1 INF-α
9.6.2 IL-6
9.6.3 Rituximab
9.6.4 Other
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Immunotherapy Drugs for Multiple Myeloma Market Size Forecast by Applications
9.10.1 Hospital
9.10.2 Drug Center
9.10.3 Clinic
9.10.4 Other
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Immunotherapy Drugs for Multiple Myeloma Analysis and Forecast
10.1 Introduction
10.2 Europe Immunotherapy Drugs for Multiple Myeloma Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Immunotherapy Drugs for Multiple Myeloma Market Size Forecast by Type
10.6.1 INF-α
10.6.2 IL-6
10.6.3 Rituximab
10.6.4 Other
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Immunotherapy Drugs for Multiple Myeloma Market Size Forecast by Applications
10.10.1 Hospital
10.10.2 Drug Center
10.10.3 Clinic
10.10.4 Other
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Immunotherapy Drugs for Multiple Myeloma Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Immunotherapy Drugs for Multiple Myeloma Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Immunotherapy Drugs for Multiple Myeloma Market Size Forecast by Type
11.6.1 INF-α
11.6.2 IL-6
11.6.3 Rituximab
11.6.4 Other
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Immunotherapy Drugs for Multiple Myeloma Market Size Forecast by Applications
11.10.1 Hospital
11.10.2 Drug Center
11.10.3 Clinic
11.10.4 Other
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Immunotherapy Drugs for Multiple Myeloma Analysis and Forecast
12.1 Introduction
12.2 Latin America Immunotherapy Drugs for Multiple Myeloma Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Immunotherapy Drugs for Multiple Myeloma Market Size Forecast by Type
12.6.1 INF-α
12.6.2 IL-6
12.6.3 Rituximab
12.6.4 Other
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Immunotherapy Drugs for Multiple Myeloma Market Size Forecast by Applications
12.10.1 Hospital
12.10.2 Drug Center
12.10.3 Clinic
12.10.4 Other
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Immunotherapy Drugs for Multiple Myeloma Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Immunotherapy Drugs for Multiple Myeloma Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Immunotherapy Drugs for Multiple Myeloma Market Size Forecast by Type
13.6.1 INF-α
13.6.2 IL-6
13.6.3 Rituximab
13.6.4 Other
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Immunotherapy Drugs for Multiple Myeloma Market Size Forecast by Applications
13.10.1 Hospital
13.10.2 Drug Center
13.10.3 Clinic
13.10.4 Other
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Immunotherapy Drugs for Multiple Myeloma Market: Competitive Dashboard
14.2 Global Immunotherapy Drugs for Multiple Myeloma Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Tonghua Dongbao Pharmaceutical
14.3.2 Sumitomo
14.3.3 Merck
14.3.4 Biogen
14.3.5 Schering-Plough
14.3.6 Roche
14.3.7 Glaxo
14.3.8 Chiron
